ARROWHEAD PHARMACEUTICALS, INC. (19)

Browse by Contract Category

Contracts

Open Market Sale Agreement, dated as of December 2, 2022, by and between Arrowhead Pharmaceuticals, Inc. and Jefferies, LLC (Filed With SEC on December 8, 2022)
First Amendment to Exclusive License and Co-Funding Agreement by and between Arrowhead Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. dated March 15, 2022 (Filed With SEC on May 10, 2022)
Collaboration and License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Horizon Therapeutics Ireland DAC, dated June 18, 2021 (Filed With SEC on August 5, 2021)
Form of RSU Agreement (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan) (Filed With SEC on August 5, 2021)
Amendment No. 3 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated January 11, 2019 (Filed With SEC on November 23, 2020)
Underwriting Agreement, dated as of December 3, 2019, among Arrowhead Pharmaceuticals, Inc. and Goldman Sachs & Co. LLC, Jefferies, LLC, and Piper Jaffray & Co., as... (Filed With SEC on December 6, 2019)
Form of Stock Option Agreement (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan) (Filed With SEC on August 5, 2021)
Form of Performance RSU Agreement (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan) (Filed With SEC on August 5, 2021)
Amendment No. 5 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated May 14, 2020 (Filed With SEC on November 23, 2020)
Amendment No. 4 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated September 19, 2019 (Filed With SEC on November 23, 2020)
Amendment No. 2 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated January 10, 2019 (Filed With SEC on November 23, 2020)
Amendment No. 1 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated October 22, 2018 (Filed With SEC on November 23, 2020)
Open Market Sale Agreement, dated as of August 5, 2020, by and between Arrowhead Pharmaceuticals, Inc. and Jefferies LLC (Filed With SEC on August 5, 2020)
Sublease agreement by and between Halozyme, Inc. and Arrowhead Pharmaceuticals Inc. dated March 3, 2020 (Filed With SEC on May 7, 2020)
Amendment No. 1 to License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated December 18, 2018 (Filed With SEC on November 25, 2019)
Amendment No. 1 to Research Collaboration and Option Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated November 14, 2019 (Filed With SEC on November 25, 2019)
Amendment No. 2 to License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated February (Filed With SEC on November 25, 2019)
Description of Registrants Securities (Filed With SEC on November 25, 2019)
Lease Agreement between Arrowhead Pharmaceuticals, Inc. and 177 Colorado Owner LLC, dated April 17, 2019 (Filed With SEC on August 5, 2019)